Compare ARES & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARES | DGX |
|---|---|---|
| Founded | 1997 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 22.6B |
| IPO Year | 2014 | 1996 |
| Metric | ARES | DGX |
|---|---|---|
| Price | $115.84 | $215.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $165.50 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.1M | 783.1K |
| Earning Date | 05-01-2026 | 04-21-2026 |
| Dividend Yield | ★ 4.87% | 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | N/A | ★ 2.24 |
| Revenue | $4,755,618,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | N/A | $7.53 |
| Revenue Next Year | $17.59 | $3.77 |
| P/E Ratio | ★ $78.35 | $96.16 |
| Revenue Growth | ★ 28.86 | 11.78 |
| 52 Week Low | $95.80 | $164.65 |
| 52 Week High | $195.26 | $217.41 |
| Indicator | ARES | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 70.70 |
| Support Level | $107.40 | $193.77 |
| Resistance Level | $128.17 | N/A |
| Average True Range (ATR) | 5.76 | 4.21 |
| MACD | -1.71 | 1.58 |
| Stochastic Oscillator | 28.27 | 92.43 |
Ares Management is one of the world's largest alternative-asset managers, with $622.5 billion in total assets under management, or AUM, including $384.9 billion in fee-earning AUM, at the end of 2025. The company has four main business segments: credit strategies ($406.9 billion in total AUM and $249.8 billion in fee-earning AUM), private equity, ($25.3 billion/$14.4 billion), real estate/real assets ($139.1 billion/$84.1 billion), and other alternatives ($51.2 billion/$36.6 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.